Spring Bank: Spring Bank Pharmaceuticals : F-star Therapeutics Announces Approval of Clinical Trial Application for FS222

(marketscreener.com) CD137/PD-L1 Bispecific Antibody for Patients with Advanced Malignancies to Enter the Clinic First-in-Human Adaptive Trial to Evaluate Safety, Pharmacology and Anti-tumor Activity CAMBRIDGE, England and CAMBRIDGE, Mass., Nov. 24, 2020 - F-star Therapeutics, a clinical-stage biopharmaceutical company dedicated...https://www.marketscreener.com/quote/stock/SPRING-BANK-PHARMACEUTICA-26786472/news/Spring-Bank-Pharmaceuticals-F-star-Therapeutics-Announces-Approval-of-Clinical-Trial-Application-f-31858616/?utm_medium=RSS&utm_content=20201124